06/16/2026
The Supreme Court has made it harder to pursue certain patent claims tied to so-called “skinny label” products.
For companies operating in regulated industries, particularly pharmaceuticals, the decision could reshape how patent disputes are pleaded and what evidence courts expect to see before a case moves forward.
The ruling arrives at a time when skinny label strategies continue attracting significant attention across the industry, making the Court’s guidance particularly consequential for patent owners and market participants alike.
In his latest article, Kevin Bastuba, Patent Group Chair at Founders Legal, examines the decision, its implications for inducement claims, and what companies should take away from the Court’s latest patent ruling.
Visit the link in our bio to read the full article.
If your company is evaluating patent enforcement, litigation strategy, or broader intellectual property protection, schedule a consultation with our patent team through the link in our bio.